Form 4 for KRSA Korsana Biosciences, Inc.
Accepted 2026-08-18 17:21:27 ET · period of report 2026-08-14 · accession 0001193125-26-355707 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-18 17:21 | 2026-08-14 | KRSA | Graul Regina Margaret | See Remarks, Dir | M - OptEx | $3.30 | +55.8K | 156.2K | +56% | +$184.3K |
| D | 2026-08-18 17:21 | 2026-08-14 | KRSA | Graul Regina Margaret | See Remarks, Dir | F - Tax | $3.79 | -48.6K | 107.5K | -31% | -$184.3K |
| D | 2026-08-18 17:21 | 2026-08-14 | KRSA | Graul Regina Margaret | See Remarks, Dir | M - OptEx | $0.00 | -55.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, no par value | 2026-08-14 | M | A | 55,849 | $3.30 | 156,152 | D | — | — | (F1) The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person. |
| 2 | Common | Common Stock, no par value | 2026-08-14 | F | D | 48,629 | $3.79 | 107,523 | D | — | — | (F2) The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cashless exercise, forfeiting options to purchase 48,629 shares as payment to the Issuer for the full exercise price. |
| 3 | Derivative | Option to Purchase | 2026-08-14 | M | D | 55,849 | $0.00 | 0 | D | $3.30 · — to 2034-08-03 | 55,849 Common Stock | (F1) The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person. (F1) The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person. |